Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Construction in Progress: 2018-2023

  • China SXT Pharmaceuticals' Construction in Progress fell 3.77% to $349,390 in Q1 2023 from the same period last year, while for Mar 2023 it was $349,390, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $349,390 for FY2023, which is 3.77% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Construction in Progress stood at $349,390 for Q1 2023, which was up 1.82% from $343,153 recorded in Q3 2022.
  • China SXT Pharmaceuticals' 5-year Construction in Progress high stood at $649,235 for Q1 2019, and its period low was $180,000 during Q3 2019.
  • For the 3-year period, China SXT Pharmaceuticals' Construction in Progress averaged around $353,961, with its median value being $355,614 (2021).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Construction in Progress slumped by 68.58% in 2019, and later soared by 149.70% in 2020.
  • Over the past 5 years, China SXT Pharmaceuticals' Construction in Progress (Quarterly) stood at $180,000 in 2019, then surged by 149.70% to $449,464 in 2020, then fell by 20.22% to $358,569 in 2021, then fell by 4.30% to $343,153 in 2022, then decreased by 3.77% to $349,390 in 2023.
  • Its Construction in Progress was $349,390 in Q1 2023, compared to $343,153 in Q3 2022 and $363,078 in Q1 2022.